Non-catalytic FAK inhibitors for lung fibrosis
Official title: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
Funded at Faknostics, LLC · NIH-11400394 · Data updated 2026-11-12
A new treatment approach is being explored to slow or reverse lung fibrosis by targeting FAK proteins that drive stiffening and scarring in IPF patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Faknostics, LLC NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | August 10, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $662,561 |
| NIH project number | 5R42HL162392-04 |
| Project ID | NIH-11400394 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with idiopathic pulmonary fibrosis or related progressive fibrosing lung diseases could be relevant for translational studies and future trials.
✕Less likely to help
Patients with non-fibrotic lung diseases or unrelated conditions are unlikely to benefit.
What this research studies
IPF is a serious lung disease with limited options for reversing damage. This project focuses on non-catalytic FAK inhibitors to interfere with the pathways that cause scarring in the lungs. Researchers will use cell-based and molecular approaches to understand how these inhibitors affect fibrotic processes and fibrosis-related cell behavior. The goal is to develop a new therapeutic strategy that could improve lung function and quality of life for people with IPF.
Why it matters
Potential benefit: If successful, this work could lead to a new treatment that slows or reverses lung fibrosis and improves breathing.
How similar studies have gone: Past fibrosis drugs have had limited success; this approach is building on the idea that targeting FAK may yield new benefits, with some prior evidence of FAK’s role in fibrosis.
Where this research is happening
-
Faknostics, LLC
Phoenix, United States Active
Researchers
- Principal investigator: Marlowe, Timothy a — Faknostics, LLC
- Study coordinator: Marlowe, Timothy a
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.